{"denoms":[{"counts":[{"groupId":"BG000","value":"26"}],"units":"Participants"}],"groups":[{"description":"All doses of samalizumab were individualized based on the participant's body surface area in mg/m\\^2 based on screening height and weight. Participants were assigned to a dose cohort, ranging from 50 to 600 mg/m\\^2, and received a single IV dose of samalizumab. Participants who tolerated the drug and demonstrated at least stable disease received up to 3 additional cycles of samalizumab at the same dose originally received at a minimum of 28-day intervals and beginning no sooner than 6 weeks after the initial dose.","id":"BG000","title":"Samalizumab"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"12.14","value":"65.8629"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"18"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"23"}],"title":"B-Cell Chronic Lymphocytic Leukemia"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Multiple Myeloma"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Type of Malignancy","unitOfMeasure":"Participants"}],"populationDescription":"All participants who received at least 1 dose of samalizumab."}